Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria

PHASE4RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 12, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Chronic Spontaneous UrticariaChronic Urticaria, Idiopathic
Interventions
DRUG

omalizumab 300 mg every four weeks

"Continue standard treatment with omalizumab 300 mg every four weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12."

DRUG

omalizumab 300 mg every six weeks

"Treatment in an extended interval of omalizumab 300 mg every six weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12."

Trial Locations (1)

2100

RECRUITING

Department of Dermatology, Bispebjerg Hospital, Copenhagen

All Listed Sponsors
collaborator

Aarhus University Hospital

OTHER

lead

Simon Francis Thomsen

OTHER